پیوندهای مفید
آمار
| تعداد نشریات | 21 |
| تعداد شماره‌ها | 610 |
| تعداد مقالات | 9,029 |
| تعداد مشاهده مقاله | 67,082,972 |
| تعداد دریافت فایل اصل مقاله | 7,656,409 |
سنتز، بررسی زیست شناختی و مطالعات داکینگ مشتقات بنزایمیدازول به عنوان مهارکننده‌های آنزیم بوتیریل کولین استراز و استیل کولین استراز | ||
| شیمى کاربردى روز | ||
| دوره 19، شماره 71، تیر 1403، صفحه 247-266 اصل مقاله (798.3 K) | ||
| نوع مقاله: مقاله علمی پژوهشی | ||
| شناسه دیجیتال (DOI): 10.22075/chem.2024.31585.2204 | ||
| نویسندگان | ||
| مریم روحی؛ سکینه اصغری قراخیلی؛ زهرا قنبری مصیر* | ||
| گروه شیمی آلی، دانشکده شیمی، دانشگاه مازندران، بابلسر، ایران | ||
| تاریخ دریافت: 06 مهر 1402، تاریخ بازنگری: 13 دی 1402، تاریخ پذیرش: 11 بهمن 1402 | ||
| چکیده | ||
| فرضیه کولینرژیک یکی از فرضیه های بیماری آلزایمر است که نشان دهنده رابطه بین شروع و پیشرفت بیماری است. یکی از راه‌های اصلی افزایش سطح استیل کولین مهار آنزیم‌های کولین استراز است. هسته بنزایمیدازول به دلیل تمایل زیاد به انواع آنزیم‌ها و گیرنده‌های پروتئینی در تحقیقات شیمی دارویی اهمیت زیادی دارد. مطالعه حاضر در راستای سنتز مشتقات بنزایمیدازول، با هدف بررسی فعالیت مهارکنندگی آنزیم‌های بوتیریل کولین استراز (BuChE) و استیل کولین استراز (AChE) انجام شد. در این مطالعه تجربی، ابتدا فراورده 2-(کلرومتیل) بنزایمیدازول (2) به دست آمد، سپس سه مشتق نهایی بنزایمیدازولی 3، 4 و 5، به ترتیب از واکنش 1 میلی‌مول از این فراورده و 1 میلی‌مول پی‌پرازین یا N-فنیل‌پی‌پرازین و یا 2-فنیل‌اتان-1-آمین تهیه شدند. ساختار ترکیبات تهیه شده با روش‌های طیف سنجی 1H-NMR 13C-NMR, و FT-IR تائید شدند. مهار آنزیم BuChE و AChE با استفاده از تست المن مورد ارزیابی قرار گرفت. نتایج حاصل از این تست قدرت مهارکنندگی قابل توجه این ترکیبات را نشان داد. ترکیب 5 با µM 28/0 = IC50 بیشترین مهار را در مقابل آنزیم BuChE نشان داد. فعالیت مهاری ترکیب 5 در برابر BuChE بهتر از دونپزیل بود. علاوه بر این، برهمکنش ترکیب 5، داروهای گالانتامین و ریواستیگمین با آنزیم BuChE با استفاده از مطالعات داکینگ مورد بررسی قرار گرفت. در این مطالعات نیز ترکیب 5 با میزان انرژی kcal/mol 88/8- بهترین برهمکنش را با جایگاه فعال گیرنده نشان داد. با توجه به نتایج به‌دست آمده، ترکیب 5 امیدوارکننده‌ترین ترکیب برای توسعه مشتقات بنزایمیدازول در مقابل بیماری الزایمر می‌باشد. | ||
| کلیدواژه‌ها | ||
| بنزایمیدازول؛ پی‌پیرازین؛ استیل کولین استراز؛ بوتیریل‌کولین‌استراز؛ مطالعات داکینگ | ||
| عنوان مقاله [English] | ||
| Synthesis, biological investigation, and docking studies of benzimidazole derivatives as butyrylcholinesterase and acetylcholinesterase inhibitors | ||
| نویسندگان [English] | ||
| Maryam Rouhi؛ Sakineh Asghari؛ Zahra Ghanbari Masir | ||
| Department of Organic Chemistry, Faculty of Chemistry, University of Mazandaran, Babolsar, Iran | ||
| چکیده [English] | ||
| The cholinergic hypothesis is one of the hypotheses of Alzheimer's disease that shows the relationship between the onset and progression of the disease. One of the main ways to increase the level of acetylcholine is to inhibit cholinesterase enzymes. The benzimidazole core is very important in medicinal chemistry research due to its high affinity to various enzymes and protein receptors. The present study was conducted in the synthesis of benzimidazole derivatives with the aim of investigating butyrylcholinesterase (BuChE) and acetylcholinesterase (AChE) inhibitory activity. In the first step of experimental study, the product 2-(chloromethyl)benzimidazole (2) was obtained, then the final three benzimidazole derivatives 3, 4, and 5 were synthesized from the reaction of 1 mmol 2-(Chloromethyl)benzimidazole and 1 mmol of piperazine, N-phenylpiperazine, and 2-phenylethan-1-amine, respectively. The structure of the prepared compounds was confirmed by 1H-NMR, 13C-NMR, and FT-IR spectroscopic methods. The ability of the compounds to inhibit AChE and BuChE was evaluated using Ellman’s assay. The results of this test showed the significant inhibitory activities of these compounds. Compound 5 with IC50 = 0.28 µM showed the highest inhibition against BuChE enzyme. The inhibitory activity of compound 5 against BuChE was better than donepezil. In addition, the interaction of compound 5, galantamine, and rivastigmine with BuChE enzyme was investigated using docking studies. In these studies, compound 5 with an energy value of -8.88 kcal/mol showed the best interaction with the active site of the receptor. According to the obtained results, compound 5 is the most promising compound for the development of benzimidazole derivatives against Alzheimer's disease. | ||
| کلیدواژه‌ها [English] | ||
| Benzimidazole, Piperazine, Acetylcholinesterase, butyrylcholinesterase, Docking studies | ||
| مراجع | ||
|
[1]. Walia, R., Hedaitullah, M., Naaz, S. F., Iqbal, K., & Lamba, H. S. (2011). Benzimidazole derivatives-an overview. Int. J. Res. Pharm. Chem, 1(3), 565-74.
[2]. Yadav, G., & Ganguly, S. (2015). Structure activity relationship (SAR) study of benzimidazole scaffold for different biological activities: A mini-review. European journal of medicinal chemistry, 97, 419-443.
[3]. Sharpe, M., Jarvis, B., & Goa, K. L. (2001). Telmisartan: a review of its use in hypertension. Drugs, 61(10), 1501-1529.
[4]. Onor, M. L., Trevisiol, M., & Aguglia, E. (2007). Rivastigmine in the treatment of Alzheimer’s disease: an update. Clinical interventions in aging, 2(1), 17-32.
[5]. Whitehouse, P. J., Price, D. L., Clark, A. W., Coyle, J. T., & DeLong, M. R. (1981). Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society, 10(2), 122-126.
[6]. Braak, H., & Braak, E. (1991). Neuropathological stageing of Alzheimer-related changes. Acta neuropathologica, 82(4), 239-259.
[7]. Bullock, R., Touchon, J., Bergman, H., & Gambina, G. (2005). Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Current medical research and opinion, 21(8), 1317.
[8]. Ritchie, C. W., Ames, D., Clayton, T., & Lai, R. (2004). Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease. The American Journal of Geriatric Psychiatry, 12(4), 358-369.
[9]. Rösler, M., Bayer, T., Anand, R., Cicin-Sain, A., Gauthier, S., Agid, Y., ... & Gharabawi, M. (1999). Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trialCommentary: Another piece of the Alzheimer's jigsaw. Bmj, 318(7184), 633-640.
[10]. Azaresh, E., & Rajabi, M. (2020). Determination of anti-dementia drugs in wastewater, serum and human urine samples by hollow fiber liquid phase microextraction coupled with high performance liquid chromatography. Applied Chemistry, 15(56), 39-50.
[11]. Greig, N. H., Utsuki, T., Ingram, D. K., Wang, Y., Pepeu, G., Scali, C., ... & Lahiri, D. K. (2005). Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer β-amyloid peptide in rodent. Proceedings of the National Academy of Sciences, 102(47), 17213-17218.
[12]. Ozadali-Sari, K., Küçükkılınç, T. T., Ayazgok, B., Balkan, A., & Unsal-Tan, O. (2017). Novel multi-targeted agents for Alzheimer's disease: Synthesis, biological evaluation, and molecular modeling of novel 2-[4-(4-substitutedpiperazin-1-yl) phenyl] benzimidazoles. Bioorganic chemistry, 72, 208-214.
[13]. Wu, W. L., Wen, Z. Y., Qian, J. J., Zou, J. P., Liu, S. M., Yang, S., ... & Shi, D. H. (2022). Design, synthesis, characterization and evaluation of 1, 3, 5-triazine-benzimidazole hybrids as multifunctional acetylcholinesterases inhibitors. Journal of Molecular Structure, 1257, 132498.
[14]. Ali, S., Asad, M. H. H. B., Maity, S., Zada, W., Rizvanov, A. A., Iqbal, J., ... & Hussain, I. (2019). Fluoro-benzimidazole derivatives to cure Alzheimer’s disease: In-silico studies, synthesis, structure-activity relationship and in vivo evaluation for β secretase enzyme inhibition. Bioorganic Chemistry, 88, 102936.
[15]. Shaquiquzzaman, M., Verma, G., Marella, A., Akhter, M., Akhtar, W., Khan, M. F., ... & Alam, M. M. (2015). Piperazine scaffold: A remarkable tool in generation of diverse pharmacological agents. European journal of medicinal chemistry, 102, 487-529.
[16]. Tripathi, P. N., Srivastava, P., Sharma, P., Tripathi, M. K., Seth, A., Tripathi, A., ... & Shrivastava, S. K. (2019). Biphenyl-3-oxo-1, 2, 4-triazine linked piperazine derivatives as potential cholinesterase inhibitors with anti-oxidant property to improve the learning and memory. Bioorganic Chemistry, 85, 82-96.
[17]. Özkay, Ü. D., Can, Ö. D., Sağlık, B. N., Çevik, U. A., Levent, S., Özkay, Y., ... & Atlı, Ö. (2016). Design, synthesis, and AChE inhibitory activity of new benzothiazole–piperazines. Bioorganic & medicinal chemistry letters, 26(22), 5387-5394.
[18]. Mozaffarnia, S., Teimuri-Mofrad, R., & Rashidi, M. R. (2020). Design, synthesis and biological evaluation of 2, 3-dihydro-5, 6-dimethoxy-1H-inden-1-one and piperazinium salt hybrid derivatives as hAChE and hBuChE enzyme inhibitors. European Journal of Medicinal Chemistry, 191, 112140.
[19]. Herres, W., & Gronholz, J. (1984). Understanding FT-IR data processing. Part, 1, 352-356.
[20]. Keeler, J. (2010). Understanding NMR spectroscopy. John Wiley & Sons.
[21]. Lopes, A. B., Wagner, P., & Gulea, M. (2019). Synthesis of Benzimidazole‐Fused Medium‐Sized N, S‐Heterocycles via Palladium‐Catalyzed Cyclizations. European Journal of Organic Chemistry, 2019(6), 1361-1370.
[22]. Ellman, G. L., Courtney, K. D., Andres Jr, V., & Featherstone, R. M. (1961). A new and rapid colorimetric determination of acetylcholinesterase activity. Biochemical pharmacology, 7(2), 88-95.
[23]. Jalili-Baleh, L., Nadri, H., Moradi, A., Bukhari, S. N. A., Shakibaie, M., Jafari, M., ... & Foroumadi, A. (2017). New racemic annulated pyrazolo [1, 2-b] phthalazines as tacrine-like AChE inhibitors with potential use in Alzheimer's disease. European Journal of Medicinal Chemistry, 139, 280-289.
[24]. https://www.rcsb.org/
[25]. Heidari, A., Valikhani Fard, N., Noshiranzadeh, N., & Bikas, R. (2019). Synthesis of new dipeptides based on uracil and thymine and investigation of the molecular docking of these compounds as inhibitors of quorum sensing system in Pseudomonas aeruginosa. Applied Chemistry, 14(50), 277-290.
[26]. Gholamjani Moghaddam, K., & Hashemianzadeh, M. (2015). Computational studies of the interactions between quinazolone derivatives and G-quadruplex DNA as an anticancer strategy. Applied Chemistry, 10(36), 177-186.
[27]. Salehi, M., Kubickib, M., Jafari, M., Galini, M., & Soleimani, F. (2018). Synthesis, crystal structure, spectroscopic, molecular docking and DFT Studies of two Schiff base ligands derived from DL-1-Phenylethylamine. Applied Chemistry, 13(49), 103-116.
[28]. Abedanzadeh, S., Khaghani Azar, M., & Davaeil, B. (2023). Synthesis and characterization of cyclometalated Pd (II) complex bearing tyrosine: Experimental and theoretical study of interaction with biomacromolecules. Applied Chemistry, 18(68), 217-234.
[29]. Zhong, S., Hou, Y., Zhang, Z., Guo, Z., Yang, W., Dou, G., ... & Mou, Y. (2022). Identification of novel natural inhibitors targeting AKT Serine/Threonine Kinase 1 (AKT1) by computational study. Bioengineered, 13(5), 12003-12020.
[30] Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S., & Olson, A. J. (2009). AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. Journal of computational chemistry, 30(16), 2785-2791.
[31]. Nordberg, A., Ballard, C., Bullock, R., Darreh-Shori, T., & Somogyi, M. (2013). A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer's disease. The primary care companion for CNS disorders, 15(2), 26731.
[32]. Brus, B., Kosak, U., Turk, S., Pislar, A., Coquelle, N., Kos, J., ... & Gobec, S. (2014). Discovery, biological evaluation, and crystal structure of a novel nanomolar selective butyrylcholinesterase inhibitor. Journal of medicinal chemistry, 57(19), 8167-8179.
[33]. Motebennur, S. L., Nandeshwarappa, B. P., & Katagi, M. S. (2023). Drug Candidates for the Treatment of Alzheimer’s Disease: New Findings from 2021 and 2022. Drugs and Drug Candidates, 2(3), 571-590.
[34]. Khan, Y., Rehman, W., Hussain, R., Khan, S., Malik, A., Khan, M., ... & Abdellatif, M. H. (2022). New biologically potent benzimidazole‐based‐triazole derivatives as acetylcholinesterase and butyrylcholinesterase inhibitors along with molecular docking study. Journal of Heterocyclic Chemistry, 59(12), 2225-2239.
[35]. Acar Cevik, U., Saglik, B. N., Levent, S., Osmaniye, D., Kaya Cavuşoglu, B., Ozkay, Y., & Kaplancikli, Z. A. (2019). Synthesis and AChE-inhibitory activity of new benzimidazole derivatives. Molecules, 24(5), 861.
[36]. Adalat, B., Rahim, F., Taha, M., Alshamrani, F. J., Anouar, E. H., Uddin, N., ... & Zakaria, Z. A. (2020). Synthesis of Benzimidazole–Based Analogs as Anti Alzheimer’s Disease Compounds and Their Molecular Docking Studies. Molecules, 25(20), 4828.
[37]. Belinskaia, D. A., Voronina, P. A., Krivorotov, D. V., Jenkins, R. O., & Goncharov, N. V. (2023). Anticholinesterase and Serotoninergic Evaluation of Benzimidazole–Carboxamides as Potential Multifunctional Agents for the Treatment of Alzheimer’s Disease. Pharmaceutics, 15(8), 2159.
[38]. Ozadali-Sari, K., Küçükkılınç, T. T., Ayazgok, B., Balkan, A., & Unsal-Tan, O. (2017). Novel multi-targeted agents for Alzheimer's disease: Synthesis, biological evaluation, and molecular modeling of novel 2-[4-(4-substitutedpiperazin-1-yl) phenyl] benzimidazoles. Bioorganic chemistry, 72, 208-214. | ||
|
آمار تعداد مشاهده مقاله: 160 تعداد دریافت فایل اصل مقاله: 133 |
||